Weight loss experts predict five major treatment changes likely to emerge in 2026
NEWNow you can listen to News articles!
Major advances continue in the weight loss landscape in the new year following groundbreaking research into GLP-1 medications and other methods.
Weight loss experts spoke to News Digital about their predictions for the biggest changes coming in 2026.
#1: Switch to Whole Body Treatment
Dr. Peter Balazs, a hormone and weight loss specialist in New York and New Jersey, shared that the biggest change is likely to be labeling GLP-1 medications as “multisystem metabolic modulators” rather than “simple weight loss medications.”
MORE AMERICANS MAY BE CLASSIFIED AS OBESE UNDER NEW DEFINITION, STUDY SUGGESTS
“The goal of treatment is no longer just BMI reduction, but full mitigation of cardiometabolic risk, with effects now documented on the liver, heart, kidneys and vasculature,” he said.
“We are seeing a significant reduction in major adverse cardiovascular events…and kidney disease progression,” he continued.
According to experts’ predictions, the target of GLP-1 drugs will expand beyond weight loss and diabetes. (iStock)
Philip Rabito, MD, an endocrinology, weight loss and wellness specialist in New York City, also shared that “exciting” advances are coming for weight loss medications, including GLP-1 and GIPs.
OLDER AMERICANS ARE LEAVING GLP-1 WEIGHT LOSS MEDICATIONS FOR 4 KEY REASONS
“These next-generation agents, along with new combinations including glucagon and amylin agonists, are demonstrating even more impressive weight loss results than currently available therapies, with the potential for improved tolerability and sustained results,” he told News Digital.
“There is also tremendous optimism around new federal agreements with manufacturers that aim to make these medications more accessible and affordable for the broad population of patients who need them most.”
No. 2: Most convenient dosage
The typical prescription for a GLP-1 drug is a weekly injection, but administration and dosing may change to more convenient methods in 2026, according to Balazs.
OPRAH JOINS WAVE OF CELEBRITIES WHO REVEALED DRAMATIC WEIGHT LOSS IN 2025
A 25 mg daily pill version of Novo Nordisk’s Wegovy, a semaglutide designed to treat obesity, is now approved and available for chronic weight management, offering a non-injectable option for some patients.
Balazs noted that an oral GLP-1 that is administered once a week is currently in Phase 2 trials, as well as an implant that targets three to six months of drug administration.
According to experts, incisionless weight loss procedures will become a lower risk option. (iStock)
No. 3: Less invasive surgery
In addition to the decreased risk during surgery for GLP-1 users, Balazs also predicted that incisionless metabolic surgery will become a better option.
“Incisionless endoscopic procedures, such as endoscopic sleeve gastroplasty (non-surgical weight-loss procedure that makes the stomach smaller from the inside) and duodenal mucosal rejuvenation (non-surgical procedure that restores part of the small intestine to help the body better manage blood sugar) – [may become] more durable and widely available,” he said.
TRY OUR LATEST LIFESTYLE QUIZ
“These offer significant metabolic benefits with a shorter recovery and lower risk than traditional surgery.”
Rabito agreed that the “rapid progress” in minimally invasive weight-loss procedures is “opening up powerful new options for patients who are hesitant to undergo traditional bariatric surgery.”
Bariatric surgery remains the most effective weight loss method, says a specialist. (iStock)
This route offers “a significant and lasting weight reduction with less risk, shorter recovery times and without external incisions,” added the expert.
Dr. Muhammad Ghanem, a bariatric surgeon at Orlando Health’s Weight Loss and Bariatric Surgery Institute, reiterated that surgery remains “the most successful modality for the treatment of obesity…with the greatest weight loss and longest-lasting results yet.”
No. 4: Younger LPG-1 users
As Novo Nordisk’s Wegovy has been indicated for adolescents 12 and older as a treatment for obesity, Balazs commented that pediatric use of weight-loss medications is “now a clinical reality.”
He predicted that other alternatives are likely to be approved in 2026 for younger users.
No. 5: Personalized and high-tech access
Amid the growth of artificial intelligence, Balazs predicted an expansion in clinical implementation of AI-powered weight loss methods.
CLICK HERE TO DOWNLOAD THE News APP
This could include categorizing obesity into subtypes such as “starved brain,” “emotional starvation” and “slow burn” to personalize how therapy is prescribed while moving away from “trial and error,” he said.
Ghanem agreed that there will likely be a “huge focus” on individualized testing for the causes of obesity in 2026, as it is a disease that can have “different causes in different people,” so requires different treatments.
AI and other digital opportunities will drive greater access for patients looking to lose weight, experts say. (iStock)
The doctor anticipates that more patients will seek treatment combinations and comprehensive programs.
“Patients are more aware that we now have some weapons in our arsenal to combat obesity and [they] We are looking for a multidisciplinary and holistic approach,” said Ghanem.
CLICK HERE FOR MORE HEALTH STORIES
Treatment options will also go digital with the rise of prescription digital therapies (PDTs) for weight loss, Balazs predicted.
“These are software applications that offer cognitive behavioral therapy, personalized nutrition and metabolic training through algorithms, often integrated with continuous glucose monitors and reimbursed as medical treatments,” he said.
CLICK HERE TO SUBSCRIBE TO OUR HEALTH NEWSLETTER
Ghanem added that body composition analyzers, such as DEXA scans, will likely become more widely used as awareness grows about the limitations of BMI and weight in assessing obesity.
Angelica Stabile is a lifestyle reporter for News Digital.